
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease
BLAAC PD is a research study to understand what Parkinson's disease looks like for Black
and African American communities.
BLAAC PD is happening at research centers around the United States. The study is part of
the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to
tr1 expand
BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities. BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to transform understanding of the genetics of Parkinson's disease and make that knowledge globally relevant. Type: Observational Start Date: Nov 2020 |
|
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary I1
Calliditas Therapeutics AB
IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO®
(delayed-release budesonide capsules) treatment in adult patients with primary IgA
nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in
real-world clinical practice. The main quest1 expand
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will - take part in this study for about 19 months - Have urine tests done - Have blood samples taken - Have physical examinations done Type: Interventional Start Date: Dec 2024 |
|
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants W1
Neuron23 Inc.
Parkinson Disease
Parkinson
Idiopathic Parkinson Disease
Early Parkinson Disease (Early PD)
Parkinson Disease, Idiopathic
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of
NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have
predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for
short) pathway based on their genetic p1 expand
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Type: Interventional Start Date: Jan 2025 |
|
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Bra1
W.L.Gore & Associates
AAA - Abdominal Aortic Aneurysm
A prospective, observational post-market registry collecting outcomes through a 10-year
post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA
Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE
Device) as a part of routine clinical p1 expand
A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice. Type: Observational [Patient Registry] Start Date: May 2024 |
|
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressi1
Sanofi
Multiple Sclerosis
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is
to determine the efficacy of frexalimab in delaying the disability progression and the
safety up to 36 months double-blind administration of study intervention compared to
placebo in male and female participan1 expand
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: - This event-driven study will end when the target number of 6-month cCDP events is achieved, and the study is expected to last 43 months from randomization of the first participant to the common study end. - The number of scheduled visits will be up to 25 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months. - If the prespecified number of events for 6-month cCDP is not reached by V21/W180, scheduled visits will continue every 3 months. Type: Interventional Start Date: Dec 2023 |
|
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chroni1
Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell
Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib +
venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is
either proactively reduced or reactively modified in response to adverse events (AEs). expand
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs). Type: Interventional Start Date: May 2024 |
|
The Ailliance Post-Market Clinical Study
Medtronic Spinal and Biologics
Spinal Deformity
Spinal Degenerative Disorder
Spinal Fusion Failure
Spinal Trauma
Spinal Tumor Case
The purpose of this clinical study is to collect performance and safety data for
post-market Medtronic devices indicated for cranial and/or spinal indication(s).
Subjects are enrolled and followed postoperatively to 24 months. The Ailliance clinical
study is intended to collect data congruous with1 expand
The purpose of this clinical study is to collect performance and safety data for post-market Medtronic devices indicated for cranial and/or spinal indication(s). Subjects are enrolled and followed postoperatively to 24 months. The Ailliance clinical study is intended to collect data congruous with routine clinical care practices. Type: Interventional Start Date: May 2023 |
|
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the1
InSightec
Movement Disorders
Neurology
Parkinsons Disease
This registry is a prospective, multicenter, international, single arm, observational
post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years.
The proposed registry will enroll 60 subjects and will be conducted at approximately 10
centers worldwide. expand
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide. Type: Observational [Patient Registry] Start Date: Jan 2023 |
|
Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experienc1
University of Maryland, Baltimore
Sickle Cell Disease
Vaso-occlusive Pain Episode in Sickle Cell Disease
Acute Pain
This study aims to evaluate the use of virtual reality as an adjunct to standard care for
patients with sickle cell disease experiencing vaso-occlusive crises. expand
This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises. Type: Interventional Start Date: Nov 2024 |
|
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
Yale University
Cesarean Delivery
General Anesthesia
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to
investigate the indications, mode of airway management, predisposing factors, and
obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for
cesarean delivery. expand
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery. Type: Observational Start Date: Feb 2024 |
|
Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractu1
University of Southern California
Multiple Closed Pelvic Fractures With Disruption of Pelvic Ring
Fragility Fracture
Internal Fixation
Nonoperative Care
The goal of this randomized pilot study is to assess feasibility of the trial and to
collect information to inform the design of a definitive trial. Adult patients ages 60
years or older with a low-energy lateral compression type 1 (LC1) pelvis fracture with
<10 mm initial displacement of the poste1 expand
The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy lateral compression type 1 (LC1) pelvis fracture with <10 mm initial displacement of the posterior pelvic ring will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, early internal fixation or nonoperative care with early rehabilitation, defined as at least five days of attempted mobilization by rehabilitation providers. Participants will be followed for 1 year. Type: Interventional Start Date: Nov 2024 |
|
RNA Sequencing of Discarded Tracheal Stenosis Tissue to Characterize Cellular and Molecular Pathoge1
University of Maryland, Baltimore
Tracheal Stenosis
Subglottic Stenosis
Benign tracheal stenosis is a rare but potentially life-threatening condition, typically
resulting from fibroinflammatory scarring. It can be secondary to iatrogenic etiologies
such as intubation or tracheostomy , as well as autoimmune diseases and being idiopathic.
Patients typically undergoes end1 expand
Benign tracheal stenosis is a rare but potentially life-threatening condition, typically resulting from fibroinflammatory scarring. It can be secondary to iatrogenic etiologies such as intubation or tracheostomy , as well as autoimmune diseases and being idiopathic. Patients typically undergoes endoscopic or surgical interventions to open up the airways. This project will analyze resected or biopsied tissue from patients with benign tracheal stenosis to define disease-specific RNA expression profiles. Type: Observational Start Date: Sep 2025 |
|
Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
University of Maryland, Baltimore
Glaucoma
This pilot study evaluates the biomechanical properties of the cornea in glaucoma
patients using Brillouin microscopy, a non-contact imaging technique. The study aims to
compare corneal stiffness between patients with normal-tension glaucoma, high-tension
glaucoma, and healthy controls, and to asse1 expand
This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression. Type: Observational Start Date: Sep 2025 |
|
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
University of Maryland, Baltimore
Opioid Withdrawal
Opioid Use Disorder
Opioid Craving
Evaluate individual differences in the expression of opioid withdrawal symptoms in
persons with opioid use disorder (OUD) while completing a clinically-indicated medication
taper. expand
Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper. Type: Interventional Start Date: Dec 2021 |
|
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
University of Maryland, Baltimore
Glioma
The purpose of this study is to examine the safety and feasibility of performing
hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess
the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with
infiltrating gliomas and examine the adde1 expand
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized [1-13C] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB). Type: Interventional Start Date: Aug 2020 |
|
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center
Opioid Use Disorder
Opioid Abuse and Addiction
Narcotic-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use
in adults in outpatient treatment for opioid use disorder, and who are receiving either
buprenorphine or methadone maintenance treatment. The main question it aims to answer is:
• Does semaglutide increase the1 expand
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: - Take semaglutide or a placebo every week for 12 weeks - Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires - Complete smartphone surveys sent at set times during the study Type: Interventional Start Date: Jan 2025 |
|
Multi-Center Clean Air Randomized Controlled Trial in COPD
JHSPH Center for Clinical Trials
Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-center randomized, sham-controlled clinical trial to determine the
effectiveness of an air cleaner intervention aimed at improving indoor air quality on
reducing COPD exacerbation risk and improving quality of life, functional status, rescue
medication use. expand
This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use. Type: Interventional Start Date: May 2024 |
|
Rare and Atypical Diabetes Network
University of South Florida
Diabetes Mellitus
Diabetes Mellitus Progression
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Disease
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study
of atypical diabetes.
The objective of this study is to define new forms of diabetes and the unique mechanisms
underlying these forms of atypical diabetes. The specific aims are to:
1. Identify and enroll1 expand
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes. Type: Observational Start Date: Sep 2020 |
|
Cardiopulmonary Bypass Induced Red Blood Cell Lysis
University of Maryland, Baltimore
Cardiopulmonary Bypass
Cardiac Surgery
Kidney Injury, Acute
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury,
limits will be set for safe levels of pfH following the use of CPB. These results will be
compared to existing laboratory-based methods for determining red blood cell damage to
predict CPB assist device safety1 expand
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB. Type: Observational Start Date: Mar 2022 |
|
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
State University of New York at Buffalo
Stroke
The purpose of this study is to find risk factors for hemorrhagic stroke. expand
The purpose of this study is to find risk factors for hemorrhagic stroke. Type: Observational Start Date: Jan 2025 |
|
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
Microvention-Terumo, Inc.
Wide Neck Bifurcation Intracranial Aneurysms
A prospective, multicenter, single arm, interventional study. The target patient
population for this study are adult subjects with WNBAs of the anterior and posterior
intracranial circulation. The primary effectiveness outcome of the study is adequate
intracranial aneurysm occlusion on the 1 year a1 expand
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory. Type: Interventional Start Date: Aug 2022 |
|
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
University of Maryland, Baltimore
Typhoid and/or Cholera Vaccination
This is an open-label, non-randomized study. The purpose of this study is to better
understand how vaccines against typhoid fever and cholera affect the normal immune system
and bacteria in the intestine. Patients having standard-of-care endoscopies (colonoscopy
and/or esophagogastroduodenoscopy (E1 expand
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine. Patients having standard-of-care endoscopies (colonoscopy and/or esophagogastroduodenoscopy (EGD)) will be divided into 3 groups: Group 1: Vivotif typhoid vaccination and/or Vaxchora cholera vaccination then endoscopy Group 2: Endoscopy, then Vivotif typhoid vaccination and/or Vaxchora cholera vaccination, then follow-up endoscopy Group 3: Endoscopy without vaccination. Both vaccines used in this study are licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will be asked to donate tissue, blood, saliva and stool samples for studying how the body responds to the typhoid and/or cholera vaccine. Type: Interventional Start Date: Nov 2018 |
|
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung C1
Teligene US
Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of
Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon
EGFR Mutations Only, Including L861Q, G719X, and/or S768I) expand
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I) Type: Interventional Start Date: Sep 2022 |
|
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
University of Maryland, Baltimore
Glioma
Glioblastoma
Brain Tumor
The purpose of this study is to evaluate the treatment regimen of using Laser
Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat
patients with newly diagnosed gliomas. expand
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas. Type: Interventional Start Date: Feb 2021 |
|
Enhancing Care & Outcomes for Patients During the First Postpartum Year
University of Maryland, Baltimore
Postpartum Period
Pregnancy
Hypertension, Pregnancy Induced
The United States is in the midst of a maternal mortality and morbidity crisis, with more
than half of maternal deaths occurring within the first postpartum year. Patients with
hypertensive disorders of pregnancy (HDP) and diabetes have been found to be particularly
high-risk, as they have a signif1 expand
The United States is in the midst of a maternal mortality and morbidity crisis, with more than half of maternal deaths occurring within the first postpartum year. Patients with hypertensive disorders of pregnancy (HDP) and diabetes have been found to be particularly high-risk, as they have a significantly increased risk for the development of cardiovascular disease in the long-term postpartum period. Traditionally, postpartum care has consisted of a single office visit at six weeks postpartum. Recent research has suggested that postpartum care should be an ongoing process, tailored to each woman's specifics needs. The purpose of this research study is to evaluate the effectiveness of obstetric care providers as primary care providers for patients at increased risk of maternal morbidity and mortality in the full first postpartum year. Type: Interventional Start Date: Nov 2024 |